

## 1622 MEDICAL, LLC.

### **BACKGROUND & APPLICATION REVIEW**

1. Name of the proposed Medical Marijuana Treatment Center:

1622 Medical, LLC

2. Address(es) of Medical Marijuana Treatment Center Operations:

Cultivation: 1379 Washington Street Weymouth, MA 02189

Product Manufacturing: 1379 Washington Street Weymouth, MA 02189

Dispensary: 1379 Washington Street Weymouth, MA 02189

3. Applicant is a licensee or applicant for other Medical Marijuana Treatment Center(s):

The applicant has no other applications or licenses at this time.

4. List of all required individuals and their business roles in the Medical Marijuana Treatment Center:

David B. Bristol - Contributing 5% or more of initial capital

James E. Bristol, III - Contributing 5% or more of initial capital

Stephen M. Ganley - CEO/COO/CFO

Fred Green - Director of Cultivation

Richard Nagle - Director of Security

5. List of all required entities and their roles in the Medical Marijuana Treatment Center:

No entities, other than the applicant, appear to have ownership or control interests over the proposed Medical Marijuana Treatment Center.

6. The applicant executed a Host Community Agreement with Weymouth on January 24, 2020.



7. The Commission received a municipal response from Weymouth on June 2, 2020 stating the applicant was in compliance with all local ordinances and bylaws.

### **SUITABILITY REVIEW**

8. There were no concerns arising from background checks on the individuals or entities associated with the application.
9. There were no disclosures of any past civil or criminal actions, or occupational license issues.

### **MANAGEMENT AND OPERATIONS REVIEW**

10. The applicant states that it can be operational by September 1, 2020.
11. The applicant was not required to submit proposed hours of operation. Commission staff will obtain this information during the inspectional phase.
12. The applicant submitted all applicable and required summaries of procedures for the operation of the proposed Medical Marijuana Treatment Center. The summaries were determined to be substantially compliant with the Commission's regulations.
13. The applicant submitted a summary of its plan for providing patient education materials. The plan is compliant with the Commission's regulations.
14. The applicant disclosed that it plans to perform home deliveries to registered patients. The summary of the applicant's plan is consistent with the Commission regulations and guidance documents.
15. Summary of cultivation plan:

The applicant submitted a summary of a cultivation plan that demonstrated the ability to comply with the regulations of the Commission.

16. Summary of products to be produced and/or sold (if applicable):
  - a. Rosins
  - b. Extracts
  - c. Edibles including chocolates and baked goods
  - d. Tinctures
  - e. Capsules
  - f. Terpene Juice
  - g. Water extracted hash
  - h. Topical Solutions



- i. 1622 will also offer pre-filled extract cartridges intended for vaporization.

## **RECOMMENDATION**

Commission staff recommend provisional licensure with the following conditions:

1. Final license is subject to inspection to ascertain compliance with Commission regulations;
2. Final license is subject to inspection to ascertain compliance with applicable state laws and local codes, ordinances, and bylaws;
3. The applicant shall cooperate with and provide information to Commission staff;
4. Provisional licensure is subject to the payment of the appropriate license fee; and
5. Final licensure is subject to the applicant providing Commission staff, upon inspection, with a detailed list of all proposed products to be produced with specific information as to types, forms, shapes, colors, and flavors.

The applicant has demonstrated compliance with the laws and regulations of the Commonwealth and suitability for licensure. Therefore, the applicant is recommended for provisional licensure.

